Halozyme Therapeutics SG&A Expense (Quarterly) Trends

Halozyme Therapeutics Inc (HALO)

38.46 -0.66 (-1.69%) USD | NASDAQ | Apr 25, 16:00

38.46 0.00 (0.00%) After-Hours: 20:00

SG&A Expense (Quarterly) Chart

Historical SG&A Expense (Quarterly) Data

View and export this data back to 2003. Upgrade now.

Date	Value
December 31, 2023	37.61M
September 30, 2023	35.27M
June 30, 2023	38.95M
March 31, 2023	37.36M
December 31, 2022	37.75M
September 30, 2022	34.47M
June 30, 2022	57.48M
March 31, 2022	13.83M
December 31, 2021	13.77M
September 30, 2021	13.17M
June 30, 2021	12.32M
March 31, 2021	11.06M
December 31, 2020	10.43M
September 30, 2020	11.70M
June 30, 2020	10.98M
March 31, 2020	12.63M
December 31, 2019	23.93M
September 30, 2019	17.98M
June 30, 2019	17.34M
March 31, 2019	18.01M
December 31, 2018	18.03M
September 30, 2018	14.86M
June 30, 2018	14.35M
March 31, 2018	13.56M
December 31, 2017	14.77M

Date	Value
September 30, 2017	13.33M
June 30, 2017	13.10M
March 31, 2017	12.62M
December 31, 2016	12.23M
September 30, 2016	11.60M
June 30, 2016	11.22M
March 31, 2016	10.81M
December 31, 2015	10.59M
September 30, 2015	10.23M
June 30, 2015	9.814M
March 31, 2015	9.399M
December 31, 2014	8.353M
September 30, 2014	8.587M
June 30, 2014	8.752M
March 31, 2014	10.25M
December 31, 2013	9.356M
September 30, 2013	8.135M
June 30, 2013	7.30M
March 31, 2013	7.556M
December 31, 2012	6.979M
September 30, 2012	5.634M
June 30, 2012	5.580M
March 31, 2012	6.619M
December 31, 2011	5.867M
September 30, 2011	4.264M

SG&A Expense Definition

SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

Read full definition.

SG&A Expense (Quarterly) Range, Past 5 Years

10.43M

Minimum

Dec 2020

57.48M

Maximum

Jun 2022

23.58M

Average

17.34M

Median

Jun 2019

SG&A Expense (Quarterly) Benchmarks